TACSTD2 and prostate carcinoma: Humanized 2G10 (Hu2G10) binds cancer-specific, cleaved/activated Trop2 with a high affinity (KD < 10-12 M), and effectively suppresses the growth of Trop2-positive tumors in vivo, including breast, colon, and prostate cancers 36, 57.